Search company, investor...
CureVac company logo

CureVac

curevac.com

Executives

9

CureVac Management Team

9 Team Members

CureVac has 9 executives. CureVac's current Chief Financial Officer is Pierre Kemula.

Name

Work History

Title

Status

Pierre Kemula

Chief Financial Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Pierre Kemula

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Financial Officer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

This profile has not been claimed.

Highlight your management team’s expertise.

Compare CureVac to Competitors

Recode Therapeutics Logo
Recode Therapeutics

ReCode Therapeutics is a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. The SORT LNP platform is the foundation for ReCode’s pipeline of disease-modifying mRNA and gene correction therapeutics. ReCode’s lead programs are focused on primary ciliary dyskinesia and cystic fibrosis. ReCode is leveraging its SORT LNP platform and nucleic acid technologies to expand its pipeline with therapeutics that use mRNA-mediated replacement and gene correction in target organs with precision targeting of disease-relevant cells. Recode Therapeutics was founded in 2015 and is based in Menlo Park, California.

Ethris Logo
Ethris

Ethris is paving a new path from genes to therapeutic proteins using its messenger RNA technology platform, which enables the discovery, design and development of transcript therapies that restore missing functions in patients' cells and tissues. Ethris is advancing transcript therapies to transform the treatment of disease.

BioNTech Logo
BioNTech

BioNTech is developing personalized immunotherapies to help the treatment of people with cancer and other debilitating diseases.

Moderna Therapeutics Logo
Moderna Therapeutics

Moderna Therapeutics (NASDAQ:MRNA) is a Cambridge, Massachusetts-based biotechnology company that is focused on drug discovery and drug development based on messenger RNA. The company creates synthetic mRNA that can be injected into patients to help them create their own therapies.

A
Arcturus Therapeutics

Arcturus Therapeutics (NASDAQ: ARCT) focuseS on the discovery and development of therapeutic modalities to pursue RNA interference (RNAi) solutions for rare diseases for which there is no adequate treatment.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.